Clinical trial
Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria
NCT00055198 · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Industry · Terminated
Key facts
| NCT number | NCT00055198 |
|---|---|
| Title | Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria |
| Official title | A Compassionate Use Protocol for Intravenous Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria That Cannot be Adequately Treated With Currently Available Therapy |
| Lead sponsor | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Gram-Positive Bacterial Infections |
| Intervention type | Drug |
| Interventions | daptomycin |
| Enrollment | 75 |
| Start date | Dec 19, 2002 |
| Primary completion | Jan 26, 2004 |
| Completion | Jan 26, 2004 |
| First posted | Feb 21, 2003 |
| Last update posted | Jun 14, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: